- Home
- DOMH vs APVO Comparison
DOMH vs APVO Comparison
Compare DOMH & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- APVO
- Stock Information
- Founded
- DOMH 1967
- APVO 2016
- Country
- DOMH United States
- APVO United States
- Employees
- DOMH N/A
- APVO N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- APVO Health Care
- Exchange
- DOMH Nasdaq
- APVO Nasdaq
- Market Cap
- DOMH 83.3M
- APVO 4.1M
- IPO Year
- DOMH N/A
- APVO N/A
- Fundamental
- Price
- DOMH $5.21
- APVO $2.96
- Analyst Decision
- DOMH
- APVO Strong Buy
- Analyst Count
- DOMH 0
- APVO 1
- Target Price
- DOMH N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- DOMH 302.6K
- APVO 6.7M
- Earning Date
- DOMH 08-07-2025
- APVO 08-07-2025
- Dividend Yield
- DOMH 6.07%
- APVO N/A
- EPS Growth
- DOMH N/A
- APVO N/A
- EPS
- DOMH N/A
- APVO N/A
- Revenue
- DOMH $24,891,000.00
- APVO N/A
- Revenue This Year
- DOMH N/A
- APVO N/A
- Revenue Next Year
- DOMH N/A
- APVO N/A
- P/E Ratio
- DOMH N/A
- APVO N/A
- Revenue Growth
- DOMH 630.80
- APVO N/A
- 52 Week Low
- DOMH $0.83
- APVO $2.81
- 52 Week High
- DOMH $13.58
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- DOMH 49.52
- APVO 33.90
- Support Level
- DOMH $5.08
- APVO $2.92
- Resistance Level
- DOMH $6.08
- APVO $3.19
- Average True Range (ATR)
- DOMH 0.53
- APVO 1.05
- MACD
- DOMH -0.04
- APVO 0.24
- Stochastic Oscillator
- DOMH 25.45
- APVO 2.23
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.